On August 13, 2025, Opus Genetics, Inc. announced its financial results for the second quarter ended June 30, 2025. The company reported license and collaboration revenue of $2.9 million, an increase from $1.1 million in the same period in 2024, primarily driven by reimbursement of R&D services from its collaboration with Viatris, Inc.
The net loss for the second quarter was $7.4 million, or $(0.12) per basic and diluted share, compared to a net loss of $7.8 million, or $(0.30) per share, for the second quarter of 2024. General and administrative expenses increased to $5.8 million from $3.4 million, mainly due to legal, patent, and payroll costs.
Research and development expenses were $6.0 million, a slight decrease from $6.1 million in the prior-year period, due to lower manufacturing and consulting costs partially offset by increased clinical trial and toxicology expenses. As of June 30, 2025, Opus Genetics held $32.4 million in cash and cash equivalents, which is expected to fund operations into the second half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.